Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating an expectation for the industry to outperform the overall market [2][21]. Core Insights - The pharmaceutical sector saw a weekly increase of 1.8%, outperforming the Shanghai Composite Index, which declined by 0.6% [2][3]. - The overall valuation of the pharmaceutical sector is at 28.4 times PE for 2025E, ranking 6th among 31 primary industries [4][9]. - Notable events include the IPO of 恒瑞医药 (Hengrui Medicine) on May 23, raising approximately 98.9 billion HKD, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [10]. - The ASCO annual meeting highlighted impressive clinical data for several domestic innovative drugs, including those from 科伦博泰 (Kelun Biotech) and 荣昌生物 (Rongchang Biotech) [10]. - 三生制药 (3SBio) entered into a collaboration with Pfizer worth over 6 billion USD, which includes an upfront payment of 1.25 billion USD and potential milestone payments [11]. Market Performance Summary - The pharmaceutical sector's performance was the best among 31 sub-industries, with various segments showing different growth rates: - Raw materials (+4.0%) - Chemical preparations (+3.5%) - Other biological products (+4.1%) - Vaccines (-0.9%) [4][3]. Key Events Recap - The report emphasizes the significance of the collaboration between 三生制药 and Pfizer, which sets a new record for licensing deals in the industry [11]. - The U.S. Department of Health and Human Services announced the implementation of a "Most Favored Nation" pricing standard for prescription drugs, aiming to align U.S. prices with those in comparable economies [11]. Investment Recommendations - The report suggests focusing on domestic innovative drug companies such as 三生制药, 恒瑞医药, and 科伦药业, among others, due to their promising performance and potential for growth [2][11]. - It also highlights the potential for more unprofitable innovative drug companies to go public, which could provide further investment opportunities in the sector [2].

Market Overview - During the week of May 19 to May 23, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 3348.37 points, down 0.57% for the week, the Shenzhen Component Index at 10132.41 points, down 0.46%, and the ChiNext Index at 2021.50 points, down 0.88% [2] - Approximately 31% of stocks experienced gains during the week, with 93 stocks rising over 15% and 18 stocks falling over 15%. The pharmaceutical, non-ferrous metals, automotive, home appliances, and coal sectors showed the highest gains, while the computer, machinery, communication, electronics, and non-bank financial sectors saw declines [2] Top Gainers - The top-performing stock was Sanofi Biotech (三生国健), which surged by 99.96% during the week, followed by Huibo Yuntong (慧博云通) with a 69.00% increase. Other notable gainers included Binhai Energy (滨海能源), Liren Lizhuang (丽人丽妆), and Haichen Pharmaceutical (海辰药业), all of which saw gains exceeding 50% [4][5] Sanofi Biotech's Performance - Sanofi Biotech operates in the biotechnology sector, focusing on innovative antibody drug research and has a mature integrated platform for research, production, and sales. The company specializes in monoclonal, bispecific, and multifunctional recombinant proteins [5] - Following the announcement of a collaboration with Pfizer for a dual-target antibody product, Sanofi Biotech's stock hit the daily limit up on May 20 and 21, with significant trading volumes. However, on May 23, the stock experienced a sharp decline, dropping over 10% during intraday trading and closing down more than 3% [6][7] Collaboration with Pfizer - On May 20, Sanofi Biotech announced a collaboration with Pfizer, granting exclusive global development, production, and commercialization rights for the dual-target antibody SSGJ-707, excluding mainland China. Pfizer will pay a non-refundable upfront fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion, plus a percentage of sales based on the product's performance in authorized regions [7] Market Trends in Innovative Drugs - The Chinese innovative drug sector is witnessing an increase in outbound licensing transactions, with 126 events recorded in 2024, involving upfront payments totaling $4.099 billion and a total deal value of $52.577 billion. The first quarter of 2025 also showed active outbound transactions, with 33 deals disclosed, exceeding $36.2 billion [8] Top Losers - The worst-performing stock for the week was Yuzhong Sanxia A (渝三峡A), which fell by 25.91%. Other significant decliners included Jitai Co. (集泰股份), Qifeng Precision (七丰精工), and Ningbo Ocean (宁波远洋), all of which experienced declines exceeding 18% [10][11]

Group 1 - Pfizer announced the acquisition of the global rights (excluding mainland China) for the PD-1/VEGF dual antibody drug SSGJ-707 from 3SBio for a total of $6.05 billion, marking a significant milestone for Chinese pharmaceutical innovation [1] - The global pharmaceutical landscape is shifting, with multinational companies increasingly acquiring innovative drug assets from Chinese firms, as evidenced by 29% and 31% of new drug assets being licensed from Chinese companies in 2023 and 2024, respectively [1] - The improvement in China's pharmaceutical industry capabilities in target discovery, molecular design, and R&D efficiency has led to a stronger position in the PD-1/VEGF dual antibody segment, with Chinese companies holding significant influence [1] Group 2 - The success of Chinese innovative drugs is breaking the traditional "follow-up innovation" model, with higher-quality Chinese drugs and R&D pipelines beginning to explore overseas markets [2] - The growth of Chinese innovative drugs is attributed to a decade of technological accumulation and a keen understanding of global pharmaceutical industry changes, necessitating a focus on three strategic support points: seizing innovation leadership, building industry moats, and establishing global influence [2] - Chinese pharmaceutical companies are encouraged to focus on core capabilities in innovation while balancing the need for external licensing opportunities and long-term commitment to R&D [3]

Core Insights - The CD47 target was once highly sought after by global pharmaceutical companies, likened to the next PD-1, but has since faced significant challenges and failures in drug development [1][3][14] - Despite the setbacks, companies like I-Mab and Kangfang Biotech remain optimistic about the potential of CD47-targeted therapies, with ongoing clinical trials [5][9][14] Industry Overview - CD47 is a transmembrane glycoprotein expressed on various cancer cells, which helps tumors evade the immune system by sending a "don't eat me" signal to macrophages [3][5] - Major pharmaceutical companies, including Gilead and Pfizer, have made substantial investments in CD47-targeted therapies, with Gilead acquiring Forty Seven for $4.9 billion, but faced failures in clinical trials [3][5][12] - In China, over 20 clinical approvals for CD47-targeted drugs have been granted, but many companies, including Hengrui and Innovent, have halted their trials due to disappointing results [4][5][12] Company Developments - I-Mab is advancing two Phase III clinical trials for its CD47-targeted therapies, while Kangfang Biotech is conducting multiple trials for its drug, Lefanlimab [5][9] - I-Mab's approach to CD47 is distinct, as it utilizes a non-antibody drug that binds more selectively to cancer cells, potentially reducing toxicity and improving dosing [8][9] - Kangfang Biotech is optimizing its drug structure to minimize red blood cell aggregation, which is a significant issue with CD47 antibodies [9][12] Market Sentiment - The global pharmaceutical industry has invested nearly 100 billion RMB in CD47 research without a successful drug to date, leading to a cautious approach from investors and companies [5][12] - There is a growing sentiment that the investment climate for innovative drugs is improving, with increased activity from investment funds in the sector [11][16]

Group 1 - The company signed an exclusive agreement with Pfizer for the global development, production, and commercialization rights of its PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1] - The agreement also includes a tiered sales revenue sharing based on product sales in the licensed regions, and Pfizer will purchase $100 million worth of common stock in the company upon the agreement's effective date [1] - The company maintains its profit forecast, expecting net profits of 2.328 billion, 2.612 billion, and 2.938 billion yuan for 2025-2027, with corresponding EPS of 0.97, 1.09, and 1.23 yuan per share, resulting in a current PE of 9.3, 8.3, and 7.4 times [1] Group 2 - SSGJ-707 has shown excellent ORR and DCR in the treatment of NSCLC patients, indicating its best-in-class potential, and has received breakthrough therapy designation from the National Medical Products Administration for first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC [2] - The company is advancing clinical research for SSGJ-707 in other areas, including colorectal cancer and gynecological tumors, and has received FDA IND approval [2] - The company’s existing products, such as Tebentafusp, are expected to see growth due to successful negotiations for zero price reduction in 2024 and the addition of new indications, contributing to cash flow [2]

Core Viewpoint - The collaboration between 3SBio and Pfizer for SSGJ-707 marks a significant milestone in the Chinese biopharmaceutical industry, with a total upfront payment of $1.25 billion and potential milestone payments reaching up to $4.8 billion, indicating strong market confidence in the drug's potential [1][2]. Group 1: Licensing Agreement and Financial Implications - 3SBio has granted Pfizer global development, production, and commercialization rights for SSGJ-707 outside of mainland China while retaining rights for mainland China and granting Pfizer commercialization options [1]. - The agreement includes a non-refundable upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion based on development, regulatory approvals, and sales [1]. - Additionally, 3SBio will receive a tiered sales royalty based on product sales in the licensed regions [1]. Group 2: Clinical Development and Pipeline - SSGJ-707 has shown significant anti-tumor activity and good safety in Phase II clinical trials, positioning it as a potential best-in-class therapy [2]. - The drug is currently undergoing four Phase II clinical studies in China, targeting various cancers including PD-L1 positive non-small cell lung cancer (NSCLC) and advanced gynecological tumors [2]. - Future catalysts for SSGJ-707 include Pfizer's overseas clinical progress, advancements in domestic Phase III trials, and data releases from major conferences like ASCO [2]. Group 3: Existing Product Portfolio and Growth Potential - 3SBio's existing core products are mature and leading in their respective segments, with expected stable growth [2]. - Key products include Terbinafine, which is the company's top-selling product, and Erythropoietin, which has new indications covered by insurance, opening up significant market potential [2]. - The company is also focusing on oral paclitaxel and other promising candidates in its pipeline, indicating a robust growth strategy [3]. Group 4: Financial Forecast and Market Valuation - The projected peak sales for SSGJ-707 are estimated at $8.5 billion, with a 10% sales royalty contributing to a market value of approximately 35 billion [4]. - The domestic peak sales are estimated at $5 billion, contributing an additional 15 billion in market value [4]. - The total target market capitalization is around 80 billion, with significant adjustments to net profit forecasts for 2025-2027, reflecting strong growth expectations [4].

Group 1 - The core point of the article is the licensing agreement between 3SBio and Pfizer for the development and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1][2] - SSGJ-707 has shown promising clinical results in non-small cell lung cancer (NSCLC) with high objective response rates (ORR) and disease control rates (DCR), indicating its best-in-class potential [2] - The drug has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China and IND approval from the FDA, with ongoing clinical studies for other cancers [2] Group 2 - The company expects steady growth in its core products, including Tezspire and Mandi, in 2024, along with expansion in indications and formulations [3] - The company has established four new collaborations in 2024, enhancing its commercial footprint and product portfolio [3] - Revenue forecasts for the company have been adjusted upwards, with projected total revenues of 18.244 billion, 12.752 billion, and 14.731 billion yuan for 2025-2027, and corresponding net profits of 8.575 billion, 3.413 billion, and 4.102 billion yuan [3]

Group 1 - The company signed a licensing agreement with Pfizer for the PD1×VEGF dual antibody SSGJ707, granting Pfizer global rights (excluding mainland China) for development, production, and commercialization, with an upfront payment of $1.25 billion and potential milestone payments of $4.8 billion [1] - The $1.25 billion upfront payment sets a record for Chinese innovative drug licensing out, indicating strong market validation for the PD1×VEGF dual antibody sector [1] - The clinical development speed of SSGJ707 in the U.S. is expected to be rapid due to Pfizer's robust clinical development platform and commercialization system [1] Group 2 - The company has four mid-to-late stage clinical assets (IL17, IL1β, IL4R, IL5 monoclonal antibodies), each projected to generate over $1 billion in revenue, with IL17 expected to commercialize in 2025 [2] - The company forecasts revenue growth from 2025 to 2027, estimating revenues of 10.201 billion, 11.494 billion, and 13.153 billion yuan, with year-on-year growth rates of 12.0%, 12.7%, and 14.4% respectively [2] - The company anticipates net profit growth during the same period, projecting net profits of 2.345 billion, 2.648 billion, and 3.027 billion yuan, with growth rates of 12.2%, 12.9%, and 14.3% respectively [2]

金十图示：2025年05月23日（周五）美股热门股票行情一览（美股盘中） 6537.40亿市值 5134.22亿市值 5055.79亿市值 354.30 565.41 1188.00 -3.67(-1.03%) +0.03(0.00%) -4.73(-0.83%) 埃克森美孚 甲骨文 P&G 宝浩 3872.42亿市值 4418.24亿市值 4361.14亿市值 155.52 102.52 165.17 -0.45(-0.44%) -1.79(-1.14%) +0.14(+0.08%) 强生 美国银行 ss) 家得宝 101 3669.74亿市值 3602.39亿市值 3248.50亿市值 152.52 362.44 43.13 -0.09(-0.06%) -3.69(-1.01%) -0.18(-0.42%) 阿斯麦 T-Mobile US Inc 可口可乐 (acabela ASML 2737.56亿市值 3084.44亿市值 2860.00亿市值 727.21 71.66 241.10 +0.52(+0.73%) -13.49(-1.82%) +0.28(+0.12%) 赛富时 t | 联合健康 cis ...

Core Viewpoint - Heng Rui Pharmaceutical officially listed on the Hong Kong Stock Exchange on May 23, 2023, marking a significant milestone in its internationalization strategy and achieving the largest financing scale in the Hong Kong pharmaceutical sector since 2020 [1][9]. Group 1: Listing Details - Heng Rui Pharmaceutical's IPO involved a global offering of approximately 225 million H-shares at an issue price of HKD 44.05, raising approximately HKD 9.89 billion [1]. - The stock opened at HKD 57 per share, a 29.4% increase from the issue price, and closed at HKD 55.15, a 25.2% increase [1]. - The listing is the second largest IPO in Hong Kong for 2025, following the leading battery manufacturer CATL [1]. Group 2: Company Leadership and Strategy - Vice Chairman Dai Hongbin emphasized that the listing is a crucial step for Heng Rui to enter the international capital market and accelerate its innovation and internationalization [2][3]. - The company aims to leverage this listing to enhance its global cooperation network and continue its focus on innovative research and development [3][10]. - Dai Hongbin's recent appointment as Vice Chairman reflects a strategic shift in the company's leadership, allowing him to play a more significant role in external communications and strategic planning [6]. Group 3: Historical Context and Future Outlook - Heng Rui Pharmaceutical, founded in 1970, has evolved from a local pharmaceutical factory to a significant player in the Chinese pharmaceutical industry, previously reaching a market value of over 600 billion yuan [7]. - The company has established 14 R&D centers globally and initiated over 20 overseas clinical trials, indicating its commitment to international expansion [10]. - The funds raised from the IPO will support clinical research and the development of innovative platforms, aiming to create first-in-class and best-in-class products [11].